Postconcussion syndrome: A review of pathophysiology and potential nonpharmacological approaches to treatment

Physician and Sportsmedicine

Volumn 40, Issue 4, 2012, Pages 73-87

  Maroon, Joseph C ^a   LePere, Darren B ^a   Blaylock, Russell L ^b   Bost, Jeffrey W ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b Belhaven College   (United States)

Author keywords

Chronic traumatic encephalopathy; Head trauma; Immunoexcitotoxicity; Mild traumatic brain injury; Nonpharmacological agents; Postconcussion syndrome; Sports injuries

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; ATOMOXETINE; CELECOXIB; COLECALCIFEROL; CURCUMIN; DEXAMPHETAMINE; ESCITALOPRAM; FANATREX; FISH OIL; FLUOXETINE; GABAPENTIN; GABAPENTIN ENACARBIL; GREEN TEA EXTRACT; IBUPROFEN; LUTEOLIN; MAGNESIUM; MEMANTINE; METHYLPHENIDATE; MINOCYCLINE; MODAFINIL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; QUERCETIN; RESVERATROL; SELFEMRA; TETRACYCLINE; TOPIRAGEN; TOPIRAMATE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; BLEEDING; BLURRED VISION; CALCIUM BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CONCENTRATION LOSS; CONFUSION; COORDINATION DISORDER; DECREASED APPETITE; DELIRIUM; DEPRESSION; DIET SUPPLEMENTATION; DIZZINESS; EPILEPSY; EUPHORIA; EXCITOTOXICITY; FEVER; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; INCREASED APPETITE; INFLAMMATION; INSOMNIA; IRRITABILITY; LACRIMAL FLUID; MEMORY DISORDER; MICROGLIA; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NARCOLEPSY; NAUSEA; NEPHROLITHIASIS; NEUROPATHIC PAIN; NEUROPROTECTION; OBSESSIVE COMPULSIVE DISORDER; OSTEOARTHRITIS; PANIC; PARKINSON DISEASE; PEPTIC ULCER; POSTCONCUSSION SYNDROME; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; SEIZURE; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH ULCER; VITAMIN DEFICIENCY; WEAKNESS; BRAIN CONCUSSION; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW; SPORT INJURY; SPORTS MEDICINE;

ATHLETIC INJURIES; BRAIN CONCUSSION; HUMANS; POST-CONCUSSION SYNDROME; SPORTS MEDICINE;

MLCS; MLOWN;

EID: 84874521769     PISSN: 00913847     EISSN: None     Source Type: Journal    
DOI: 10.3810/psm.2012.11.1990     Document Type: Article

References (157)

1. Guerrero JL, Thurman DJ, Sniezek JE. Emergency department visits associated with traumatic brain injury: United States, 1995-1996. Brain Inj. 2000;14(2):181-186.
2. Maroon JC, Field M, Lovell M, Collins M, Bost J. The evaluation of athletes with cerebral concussion. Clin Neurosurg. 2002;49: 319-332.
3. Hoge CW, Goldberg HM, Castro CA. Care of war veterans with mild traumatic brain injury: flawed perspectives. N Engl J Med. 2009;360(16):1588-1591.
4. Tator CH. Concussions are brain injuries and should be taken seriously. Can J Neurol Sci. 2009;36:269-270.
5. Larrabee GJ. Neuropsychological outcome, post concussion symptoms,and forensic considerations in mild closed head trauma. Semin Clin Neuropsychiatry. 1997;2(3):196-206.
6. Alexander MP. Mild traumatic brain injury: pathophysiology, natural history, and clinical management. Neurology. 1995;45(7):1253-1260.
7. McCullagh S, Feinstein A. Outcome after mild traumatic brain injury: an examination of recruitment bias. J Neurol Neurosurg Psychiatry. 2003;74(1):39-43.
8. Satz PS, Alfano MS, Light RF, et al. Persistent post-concussive syndrome: a proposed methodology and literature review to determine the effects, if any, of mild head and other bodily injury. J Clin Exp Neuropsychol. 1999;21(5):620-628.
9. Kashluba S, Casey JE, Paniak C. Evaluating the utility of ICD-10 diagnostic criteria for post-concussion syndrome following mild traumatic brain injury. J Int Neuropsychol Soc. 2006;12(1):111-118.
10. World Health Organization. International Statistical Classification of Disease and Related Health Problems 10th Revision (ICD-10): postconcussional syndrome. http://www.who.int/occupational_health/publications/en/oehicd10.pdf. Published 1999. Accessed December 17, 2012.
11. Molière. The Imaginary Invalid. 1673.
12. McCrory P. Should we treat concussion pharmacologically? Br J Sports Med. 2002;36:3-5.
13. Kushner DS. Mild traumatic brain injury: toward understanding manifestations and treatment. Arch Int Med. 1998;158(15):1617-1624.
14. Ryan LM, Warden DL. Post concussion syndrome. Int Rev Psychiatry. 2003;15(4):310-316.
15. Collie A, Makdissi M, Maruff P, Bennell K, McCrory P. Cognition in the days following concussion: comparison of symptomatic versus asymptomatic athletes. J Neurol Neurosurg Psychiatry. 2006;77(2):241-245.
16. Topal NB, Hakyemez B, Erdogan C, et al. MR imaging in the detection of diffuse axonal injury with mild traumatic brain injury. Neurol Res. 2008;30(9):974-978.
17. van der Naalt J, Hew JM, van Zomeren AH, Sluiter WJ, Minderhoud JM. Computed tomography and magnetic resonance imaging in mild to moderate head injury: early and late imaging related to outcome. Ann Neurol. 1999;46(1):70-78.
18. Voller B, Benke T, Benedetto K, Schnider P, Auff E, Aichner F. Neuropsychological, MRI and EEG findings after very mild traumatic brain injury. Brain Inj. 1999;13(10):821-827.
19. Arundine M, Tymianski M. Molecular Mechanisms of glutamatedependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci. 2004;61:657-668.
20. Blaylock RL, Maroon JC. Immunoexcitotoxicity as a central mechanism in chronic traumatic encephalopathy-a unifying hypothesis. Surg Neurol Int. 2011;2:107.
21. Luo XG, Ding JQ, Chen SD. Microglia in the aging brain: relevance to neurodegeneration. Mol Neurodegen. 2010;5:12.
22. Klegeris A, McGeer PL. Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res. 2005;2(3):355-365.
23. Politis M, Su P, Piccini P. Imaging of microglia in patients with neurodegenerative diseases. Front Pharmacol. 2012;3:96.
24. Wilson CJ, Finch CE, Cohen HJ. Cytokines and cognition-the case for a head-to-toe inflammatory paradigm. J Am Geriatr Soc. 2002;50(12):2041-2056.
25. Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and alzheimer-type pathology in aging. Neurology. 1998;50(4):986-990.
26. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and metaanalysis of observational studies. BMJ. 2003;327:128.
27. Petraglia AL, Maroon JC, Bailes JE. From the field of play to the field of combat: a review of the pharmacological management of concussion. Neurosurgery. 2012;70(6)1520-1533.
28. Blaylock RL, Maroon JC. Natural plant products and extracts that reduce immunoexcitotoxicity-associated neurodegeneration and promote repair within the central nervous system. Surg Neurol Int. 2012;3:1-19.
29. Singh G. Gastrointestinal complications of prescription and over-thecounter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. Am J Ther. 2000;7(2):115-121.
30. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340(24)1888-1899.
31. Maroon JC, Bost JW, Maroon A. Natural anti-inflammatory agents for pain relief. Surg Neurol Int. 2010;1:80.
32. Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B. N-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem. 2000;275(2):721-724.
33. Curtis CL, Rees SG, Little CB, et al. Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum. 2002;46(6):1544-1553.
34. Calder PC. N-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6 suppl):1505S-1519S.
35. Curtis CL, Harwood JL, Dent CM, Caterson B. Biological basis for the benefit of nutraceutical supplementation in arthritis. Drug Discov Today. 2004;9(4):165-172.
36. Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med. 1997;336(15):1046-1053.
37. Haqqi TM, Anthony DD, Gupta S, et al. Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci U S A. 1999;96(8):4524-4529.
38. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumor necrosis factora-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci. 2000;57(5):834-841.
39. Bernstein JE, Bickers DR, Dahl MV, Roshal JY. Treatment of chronic postherpetic neuralgia with topical capsaicin. A preliminary study. J Am Acad Dermatol. 1987;17(1):93-96.
40. Solomin SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080.
41. Maroon JC, Bost JW. Omega-3 fatty acids (fish oil) as an antiinflammatory: an alternative to nonsteriodal anti-inflammatory drugs for discogenic pain. Surg Neurol. 2006;65(4):326-331.
42. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary artery disease? Prev Med. 2004;39(1):212-220.
43. Maroon JC, Bost JW, Borden MK, Lorenz KM, Ross NA. Natural anti-inflammatory agents for pain relief in athletes. Neurosurg Focus. 2006;21(4):E11.
44. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320(5):265-271.
45. Mayer K, Meyer S, Reinholz-Muhly M, et al. Short-time infusion of fish oil-based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol. 2003;171(9):4837-4843.
46. Lonergan PE, Martin DS, Horrobin DF, Lynch MA. Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus. J Neurochem. 2004;91(1):20-29.
47. Ruff CB, Trinkhaus E, Holliday TW. Body mass and encephalisation in Pleistocene Homo. Nature. 1997;387(6629):173-176.
48. Leonard WR, Robertson ML. Evolutionary perspective on human nutrition: the influence of brain and body size on diet and metabo lism. Am J Hum Biol. 1994;6:77-88.
49. Aiello LC, Wheeler P. The expensive tissue hypothesis: the brain and the digestive system in human and primate evolution. Curr Anthropol. 1995;36(2):199-222.
50. Crawford MA. The role of dietary fatty acids in biology: their place in the evolution of the human brain. Nutr Rev. 1992;50(4 pt 2):3-11.
51. Cordain L, Watkins BA, Mann NJ. Fatty acid composition and energy density of foods available to Africanhominids. World Rev Nutr Diet. 2001;90:144-161.
52. Bailes JE, Mills JD. Docosahexaenoic acid reduces traumatic axonal injury in a rodent head injury model. J Neurotrauma. 2010;27(9):1617-1624.
53. Petraglia AL, Winkler EA, Bailes JE. Stuck at the bench: potential natural neuroprotective compounds for concussion. Surg Neurol Int. 2011;2:146.
54. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL. Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. Neuroreport. 2003;14(18):2457-2461.
55. Bazan NG, Marcheselli VL, Cole-Edwards K. Brain response to injury and neurodegeneration: endogenour neuroprotective signaling. Ann N Y Acad Sci. 2005;1053:137-147.
56. Lu DY, Tsao YY, Leung YM, Su KP. Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology. 2010;35(11):2238-2248.
57. Hogyes E, Nyakas C, Kiliaan A, Farkas T, Penke B, Luiten PG. Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience. 2003;119(4):999-1012.
58. Strokin M, Chechneva O, Reymann KG, Reiser G. Neuroprotection of rat hippocampal slices exposed to oxygen-glucose deprivation by enrichment with docosahexaenoic acid and by inhibition of hydrolysis of docosahexaenoic acid-containing phospholipids by calcium independent phospholipase A2. Neuroscience. 2006;140(2):547-553.
59. Menard C, Patenaude C, Gagne AM, Massicotte G. AMPA receptormediated cell death is reduced by docosahexaenoic acid but not by eicosapentaenoic acid in area CA1 of hippocampal slice cultures. J Neurosci Res. 2009;87(4):876-886.
60. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem. 2004;90(4):979-988.
61. Cao D, Xue R, Xu J, Liu Z. Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. J Nutr Biochem. 2005;16(9):538-546.
62. Robson LG, Dyall S, Sidloff D, Michael-Titus AT. Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals. Neurobiol Aging. 2010;31(4):678-687.
63. Bacchetta J, Ranchin B, Dubourg L, Cochat P. Vitamin D revisited: a cornerstone of health? Arch Pediatr. 2010;17(12):1687-1695.
64. Petchy WG, Hickman IJ, Duncan E, et al. The role of 25-hydroxyvitamin d deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a ran domized controlled trial. BMC Nephrol. 2009;10:41.
65. Guillot X, Semerano L, Saidenberg-Kermanac'h N, Falgarone G, Boissier MC. Vitamin D and inflammation. Joint Bone Spine. 2010;77(6):552-557.
66. Cekic M, Sayeed I, Stein DG. Combination treatment with progesterone and vitamin D hormone may be more effective than monotherapy for nervous system injury and disease. Front Neuroendocrinol. 2009;30(2):158-172.
67. Eelen G, Verlinden L, van Camp M, et al. The effects of 1alpha, 25-dihydroxyvitamin D3 on the expression of DNA replication genes. J Bone Miner Res. 2004;19(1):133-146.
68. Losem-Heinrichs E, Görg B, Redecker C, et al. 1alpha, 25-dihydroxyvitamin D3 in combination with 17 beta-estradiol reduces the cortical expression of heat shock protein-27 following experimentally induced focal cortical ischemia in rats. Arch Biochem Biophys. 2005;439(1):70-79.
69. Losem-Heinrichs E, Görg B, Schleicher A, et al. A combined treatment with 1alpha, 25-dihydroxyvitamin D3 and 17 beta-estradiol reduces the expression of heat shock protein-32 following cerebral cortical ischemia. J Steroid Biochem Mol Biol. 2004;89-90(1-5): 371-374.
70. Nemere I, Farach-Carson MC. Membrane receptors for steroid hormones: a case for specific cell surface binding sites for vitamin D metabolites and estrogens. Biochem Biophys Res Comm. 1998;248(3):443-449.
71. Stein DG. Progesterone exerts neuroprotective effects after brain injury. Brain Res Rev. 2008;57(2):386-397.
72. Atif F, Sayeed I, Ishart T, Stein DG. Progesterone with vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Mol Med. 2009;15(9-10): 328-336.
73. Cekic M, Cutler SM, Van Landingham JW, Stein DG. Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats. Neurobiol Aging. 2011;32(5):864-874.
74. Cekic M, Stein DG. Traumatic brain injury and aging: is a combination of progesterone and vitamin D hormone a simple solution to a complex problem? Neurotherapeutics. 2010;7(1):81-90.
75. Nilsen J, Brinton RD. Impact of progestins on estrogen-induced neuroprotection synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 2002;143(1):205-212.
76. Nilsen J, Brinton RD. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogenactivated protein kinase signaling. Proc Natl Acad Sci U S A. 2003; 100(18):10506-10511.
77. Brewer LD, Thibault V, Chen KC, Langub MC, Landfield PW, Porter NM. Vitamin D hormone confers neuroprotection in parallel with down-regulation of L-type calcium channels in hippocampal neurons. J Neurosci. 2001;21(1):98-108.
78. Schleithoff SS, Zitterman A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83(4):754-759.
79. Licasstro DL, Scola L, Chiapelli M, et al. Interleukin-10 promoter polymorphism in sporatic Alzheimer's disease. Genes Immun. 2003; 4(3):234-238.
80. Khoo AL, Chai LY, Koenen HJ, et al. 1,25-dihydroxyvitamin D3 modulates cytokine poroduction induced by Candida albicans: impact of seasonal variation of immune responses. J Infect Dis. 2011;203(1):122-130.
81. Chen Y, Kong J, Sun T, et al. 1,25-digyroxyvitamin D3 suppresses inflammation-induced expression of plasminogen activator inhibitor-1 by blocking nuclear factor-kB activation. Arch Biochem Biophys. 2011;507(2):241-247.
82. Anderson JL, May HT, Horne DB, et al. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol. 2010;106(7):963-968.
83. Hall LM, Kimlin MG, Aronov PA, et al. Vitamin D intake needed to maintain target serum 25-hydroxyvitamin D concentrations in participants with low sun exposure and dark skin pigmentation is substantially higher than current recommendations. J Nutr. 2010;140(3):542-550.
84. Elliott ME, Binkley NC, Carnes M, et al. Fracture risks for women in long-term care: high prevalence of calcaneal osteoporosis and hypovitaminosis D. Pharmacotherapy. 2003;23(6):702-710.
85. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777-783.
86. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med. 2002;112(8):659-662.
87. National Institutes of Health. Vitamin D: Are There Safety Concerns? Washington, DC: United States Department of Health and Human Services; 2012. http://www.nlm.nih.gov/medlineplus/druginfo/natural/929.html. Accessed December 17, 2012.
88. Araujo CC, Leon LL. Biological activities of Carcuma longa. Mem Inst Osawaldo Cruz. 2001;96(5):723-728.
89. Claeson P, Panthong A, Tuchinda P, et al. Three non-phenolic diarylheptanoids with anti-inflammatory activity from carcuma xanthorrhiza. Planta Med. 1993;59(5):451-454.
90. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through janus kinasestat pathway in t lymphocytes. J Immunol. 2002;168(12):6506-6513.
91. Talalay P, Talalay P. The importance of using scientific principles in the development of medicinal agents from plants. Acad Med. 2001;76(3):238-247.
92. Hsu HY, Wen MH. Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem. 2002;277(25):22131-22139.
93. Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of nf-kappa-b-dependent genes. Am J Physiol Gastrointest Liver Physiol. 2003;284(2):G321-G327.
94. Jachak SM. Cyclooxygenase inhibitory natural products: current status. Curr Med Chem. 2006;13(6):659-678.
95. Jiang H, Tian X, Guo Y, Duan W, Bu H, Li C. Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biol Pharmacol Bull. 2011;34(8):1194-1197.
96. Erlank H, Elmann A, Kohen R, Kanner J. Polyphenols activate Nrf2 in astrocytes via J(2)0(2), semiquinones, and quinones. Free Radic Biol Med. 2011;51(12):2319-2327.
97. Zhao SG, Li Q, Liu ZX, et al. Curcumin attenuates insulin resistance in hepatocytes by inducing Nrf2 nuclear translocation. Hepatogastroenterology. 2011;58(112):2106-2111.
98. Goepp JG. What is nuclear factor-kappa beta? Life Extension Mag. http://www.lef.org/magazine/mag2006/jul2006_report_nuclear_01.htm#AnchorFushion. Published July 2006. Accessed November 19, 2012.
99. Bengmark S. Curcumin, an atoxic antioxidant and natural NFk b, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic disease. JPEN J Parenter Enteral Nutr. 2006;30(1):45-51.
100. Plummer SM, Holloway KA, Manson MM, et al. Inhibition of Cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of nf-κ b activation via the nik/ikk signaling complex. Oncogene. 1999;18(44):6013-6020.
101. Laird MD, Sukumari-Ramesh S, Swift AE, Meiler SE, Vender JR, Dhandapani KM. Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4? J Neurochem. 2010;113(3):637-648.
102. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21(21):8370-8377.
103. Dohare P, Garg P, Jain V, Nath C, Ray M. Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behav Brain Res. 2008;193(2):289-297.
104. Zhao J, Yu S, Zheng W, Feng G, Luo G, Wang L, Zhao Y. Curcumin improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Neurochem Res. 2010;35(3):374-379.
105. Jiang J, Wang W, Sun YJ, Hu M, Li F, Zhu DY. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur J Pharmacol. 2007;561(1-3):54-62.
106. Badria FA, El-Farahaty T, Shabana AA, Hawas SA, El-Batory MF. Boswellia-curcumin preparation for treating knee osteoarthritis: a clinical evaluation. Alt Complement Ther. 2002;8(6):341-348.
107. Berman B. Turmeric. University of Maryland Medical Center. http://www.umm.edu/atlmed/ConsHerbs/Turmericch.html. Published 2004. Accessed September 22, 2011.
108. Baur JA, Sinclain DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5(6):493-506.
109. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-342.
110. Bradamante S, Barenghi L, Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc Drug Rev. 2004;22(3):169-188.
111. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int. 2009;54(2):111-118.
112. Richard T, Pawlus AD, Iglesias ML, et al. Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci. 2011;1215:103-108.
113. Gao D, Zhang X, Jiang X, et al. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci. 2006;78(22):2564-2570.
114. Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 2002;71(6):655-665.
115. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health-a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011;55(8):1129-1141.
116. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation. 2007;30(1-2):1-6.
117. Kaplan S, Bisleri G, Morgan JA, Cheema FH, Oz MC. Resveratrol, a natural red wine polyphenol, reduces ischemia-reperfusion-induced spinal cord injury. Ann Thorac Surg. 2005;80(6):2242-2249.
118. Sönmez U, Sönmez A, Erbil G, Tekmen I, Baykara B. Neuroprotective effects of resveratrol against traumatic brain injury in immature rats. Neurosci Lett. 2007;420(2):133-137.
119. Singleton RH, Yan HQ, Fellows-Mayle W, Dixon CE. Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J Neurotrauma. 2010;27(6):1091-1099.
120. Li C, Yan Z, Yang J, et al. Neuroprotective effects of resveratrol on ischemic injury mediated by modulating the release of neurotransmitter and neuromodulator in rats. Neurochem Int. 2010;56(3):495-500.
121. Karlsen A, Paur I, Bohn SK, et al. Bilberry juice modulates plasma concentration of NF-kappaB related inflammatory markers in subjects at increased risk of CVD. Eur J Nutr. 2010;49(6):345-355.
122. Yang YB, Piao YJ. Effects of resveratrol on secondary damages after acute spinal cord injury in rats. Acta Pharmacol Sin. 2003;24(7):703-710.
123. Ates O, Cayli S, Altinoz E, et al. Neuroprotection by resveratrol against traumatic brain injury in rats. Mol Cell Biochem. 2007;294(1-2):137-144.
124. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem. 2005;280(45):37377-37382.
125. Lindsay J, Laurin D, Verreault R, et al. Risk factors for Alzheimer's disease: a progressive analysis from the Canadian Study of Health and Aging. Am J Epidemiol. 2002;156(5):445-453.
126. Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J. 2001;94(12):1195-1201.
127. Johnson JW, Ascher P. Voltage-dependent block by intracellular Mg2+ of N-methyl-D-aspartate-activated channels. Biophys J. 1990;57(5):1085-1090.
128. Lin JY, Chung SY, Lin MC, Cheng FC. Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique. Life Sci. 2002;71(7):803-811.
129. Katayama Y, Maeda T, Koshinaga M, Kawamata T, Tsubokowa T. Role of excitatory amino-acid mediated ionic fluxes in traumatic brain injury. Brain Pathol. 1995;5(4):427-435.
130. Mcintosh TK, Saatman KE, Raghupathi R. Calcium and the pathogenesis of traumatic cns injury: cellular and molecular mechanisms. Neuroscientist. 1997;3(3):169-175.
131. Garfinkle L, Garfinkel D. Magnesium regulation of the glycolitic pathway and the enzymes involved. Magnesium. 1985;4:60-72.
132. Altura BM, Altura BT. Magnesium ions and contraction of vascular smooth muscles: relationship to some vascular diseases. Fed Proc. 1981;40(12):2672-2679.
133. Health DL, Vink R. Traumatic brain axonal injury produces sustained decline in intracellular free magnesium concentration. Brain Res. 1996;738(1):150-153.
134. han den Heuvel C, Vink R. Role of magnesium in traumatic brain injury. Clin Calcium. 2004;14(8):9-14.
135. Nuytten D, Van Hees J, Meulemans A, Carton H. Magnesium deficiency as a cause of acute intractable seizures. J Neurol. 1991; 238(5):262-264.
136. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69(2):338-341.
137. Lampl Y, Geva D, Gilad R, Eshel Y, Ronen L, Sarova-Pinhas I. Cerebrospinal fluid magnesium level as a prognostic factor in ischaemic stroke. J Neurol. 1998;245(9):584-588.
138. McIntosh TK, Faden AI, Yamakami I, Vink R. Magnesium deficiency exacerbates and pretreatment improves outcome following traumatic brain injury in rats: 31P magnetic resonance spectroscopy and behavioural studies. J Neurotrauma. 1988;5(1):17-30.
139. 2+ is associated with irreversible tissue injury after brain trauma. J Biol Chem. 1988;263(2):757-761.
140. Reeves SA, Gibbs RS, Clark SL. Magnesium for fetal neuroprotection. Am J Obstet Gynecol. 2011;204(3):202e.1-202e.4.
141. Saver J, Kidwell C, Leary M. The field administration of stroke therapymagnesium (FASTMAG) pilot trial. Abstract presented at: 26th International Stroke Conference; February 2001; Fort Lauderdale, FL.
142. Ghabriel MN, Thomas A, Vink R. Magnesium restores altered aquaporin-4 immunoreactivity following traumatic brain injury to a pre-injury state. Acta Neurochirurgica Supplement. 2006;96(10)402-406.
143. Okiyama K, Smith DH, Gennarelli TA, Simon RP, Leach M, McIntosh TK. The sodium channel blocker and glutamate release inhibitor BW1003C87 and magnesium attenuate regional cerebral edema following experimental brain injury in the rat. J Neurochem. 1995;64(2):802-809.
144. Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press; 1997.
145. Zierath J, Kaiserauer S, Snyder AC. Dietary patterns of amenorrheic and regularly menstruating runners. Med Sci Sports Exerc. 1986;18(suppl):S55-S56.
146. Lukaski HC. Magnesium, zinc, and chromium nutriture and physical activity. Am J Clin Nutr. 2000;72(suppl):585S-593S.
147. Lukaski HC. Micronutrients (magnesium, zinc, and copper): are mineral supplements needed for athletes? Intl J Sport Nutr. 1995;5(suppl):S74-S83.
148. Sen AP, Gulati A. The use of magnesium in traumatic brain injury. Neurotherapeutics. 2010;7(1):91-99.
149. Chen PC, Wheeler DS, Malhorta V, Odoms K, Denenberg AG, Wong HR. A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits I[kappa]B kinase activation and IL-8 gene expression. Inflammation. 2002;26(5):233-241.
150. Ghosh S, May MJ, Kopp EB. NF-kB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-260.
151. Kanakaraj P, Schafer PH, Cavender DE, et al. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med. 1998;187(12):2073-2079.
152. Thomas JA, Allen JL, Tsen M, et al. Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase. J Immunol. 1999;163(2):978-984.
153. Swantek JL, Tsen MF, Cobb MH, Thomas JA. IL-1 receptor associated kinase modulates host responsiveness to endotoxin. J Immunol. 2000;164(8):4301-4306.
154. Wheeler DS, Catravas JD, Odoms K, Denenberg A, Malhotra V, Wong HR. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibts IL-1beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutr. 2004;134(5):1039-1044.
155. Cao H, Kelly MA, Kari F, et al. Green tea increases anti-inflammatory tristetraprolin and decreases pro-inflammatory tumor necrosis factor mRNA levels in rats. J Inflamm (Lond). 2007;4:1.
156. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates t cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004; 173(9):5794-5800.
157. Seeram NP, Henning SM, Niu Y, Lee R, Scheuller HS, Heber D. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J Agric Food Chem. 2006;54(5):1599-1603.